Limit Antibiotics Use To Single Dose To Prevent Infection At Surgical Site: NCDC

NEW DELHI: It is a common practice to put patients undergoing surgery on antibiotics to prevent infections. But what should be the duration of such medication?

According to the National Centre for Disease Control (NCDC), use of antibiotics to prevent infections at the surgical site should be limited to a single dose or administered one day before the procedure. Post-procedure, NCDC says in a recent report, antibiotics should only be administered after a diagnosis of infection.

The report includes the results of a multi-centre survey led by the government agency which revealed most in-patients are given antibiotics for multiple days to prevent surgical site infection.

To determine the duration of surgical prophylaxis (the use of antibiotics for the prevention of surgical site infections) for patients, the administration of antibiotics within the previous 24 hours was observed and categorised as either one dose (S), multiple doses given in a single day (SP2), or multiple days (SP3).

The researchers found that most of the patients (91%) were put on SP3, only 1% patients were put on S and 8% patients were put on SP2.

Prolonged antibiotic administration to prevent infection is not only ineffective in reducing infections but increases antimicrobial resistance, according to the Indian Council of Medical Research (ICMR). In 2022, the ICMR issued an advisory stating most studies have suggested the efficacy of perioperative antibiotic prophylaxis for only 12 hours or less.

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre